aTYR PHARMA INC

Key metrics

Financial performance

Over the last 6 fiscal years aTYR PHARMA INC's revenue declined from $422.00K to $190.00K, a compound annual decline rate of 12.5%. Net profit margin compressed from -3844.5% to -39009.5% over the same period - every figure below comes from the company's audited annual filings.

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (720 filings)

Recent press releases

• aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update2026-05-15

  aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update | aTyr Pharma

• aTyr Pharma to Participate in Upcoming Investor Conferences2026-05-13

  aTyr Pharma to Participate in Upcoming Investor Conferences | aTyr Pharma

• aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting2026-05-11

  aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting | aTyr Pharma

• aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update2026-03-05

  aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update | aTyr Pharma

• aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2026-02-20

  aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | aTyr Pharma

Similar companies

The largest companies sharing aTYR PHARMA INC's SEC industry classification (biological products, (no diagnostic substances)).